Intravascular lymphoma masquerading as septic shock

Hiroki Kato¹ | Shinichi Miyazaki²  | Kodai Yabu³ | Yumi Sawada⁴ | Yuki Kondo² | Tadashi Aoyama⁵ | Yoshiharu Nara⁶ | Motoyoshi Yano¹

¹Department of Gastroenterology, Yokkaichi Municipal Hospital, Yokkaichi, Japan
²Department of Respiratory Medicine, Yokkaichi Municipal Hospital, Yokkaichi, Japan
³Department of Hematology, Yokkaichi Municipal Hospital, Yokkaichi, Japan
⁴Department of Dermatology, Yokkaichi Municipal Hospital, Yokkaichi, Japan
⁵Department of Anesthesiology and Critical Care Medicine, Yokkaichi Municipal Hospital, Yokkaichi, Japan
⁶Department of Pathology, Yokkaichi Municipal Hospital, Yokkaichi, Japan

Abstract
Intravascular lymphoma (IVL) is a rare type of extranodal lymphoma that selectively affects small blood vessels. We report a patient who presented with dyspnea and weight loss as well as refractory shock and multiple-organ dysfunction. The postmortem revealed disseminated involvement of an IVL but no evidence of infection.

KEYWORDS
dyspnea, intravascular lymphoma, multiple-organ dysfunction, septic shock

1 | INTRODUCTION

Intravascular lymphoma is a rare extranodal subtype of diffuse large B-cell lymphoma characterized by proliferation of lymphoma cells within the lumina of small blood vessels.¹ The median age at diagnosis is 67 years, and there is no sex predilection.²³ The clinical presentation is diverse and often includes symptoms related to organ dysfunction caused by occlusion of blood vessels. We herein describe a patient who presented with refractory shock and multiple-organ dysfunctions that mimicked septic shock. Postmortem examination revealed intravascular large B-cell lymphoma and no evidence of infection.

2 | CASE REPORT

A previously healthy 64-year-old Japanese man presented to the emergency department with dyspnea on exertion, severe fatigue, decreased appetite, and weight loss for the preceding 2 weeks. One week before his presentation, esophagogastroduodenoscopy and colonoscopy were performed because of investigation of unintentional weight loss. The result revealed advanced rectal carcinoma (Figure 1). He did not report any chills, night sweats, or fevers, was a current cigarette smoker (44 pack-year history of smoking), and reported minimal alcohol use. On examination, the patient appeared distressed, his...
respiratory rate was 30 breaths/min, oxygen saturation was 99% on oxygen supplementation at 2 L/min via nasal cannula, heart rate was 96 beats/min, blood pressure was 80/57 mm Hg, and body temperature was 35.8°C. He had conjunctival pallor, jaundice, and 4+ pitting edema in lower extremities, but no jugular venous distension, cardiac murmurs, or peripheral adenopathy.

Laboratory testing showed the following: white blood cell count = 21,000 cells/ml (neutrophils 76%, lymphocytes 16%, and monocytes 8%), hemoglobin = 9.5 g/dl, platelet count = 65,000 cells/ml, International Normalized Ratio = 1.90, fibrinogen = 343 mg/dl, sodium = 131 mmol/L, potassium = 6.5 mmol/L, chloride = 96 mmol/L, blood urea nitrogen = 101 mg/dl, creatinine = 2.05 mg/dl, uric acid = 13.8 mg/dl, glucose = 67 mg/dl, aspartate aminotransferase = 38 U/L, alanine aminotransferase = 22 U/L, alkaline phosphatase = 113 U/L, lactate dehydrogenase (LDH) level = 478 U/L, total bilirubin = 3.0 mg/dl, albumin = 1.6 g/dl, total protein = 4.9 g/dl, triglyceride = 251 mg/dl, ferritin = 900 ng/ml, soluble interleukin-2-receptor = 13,677 U/ml, procalcitonicin = 3.6 ng/ml, C-reactive protein (CRP) = 12 mg/dl, serum cortisol = 24.9 ug/dl (normal 4–18.3 ug/dl), and serum adrenocorticotropic hormone = 15.6 pg/ml (normal 7.2–63.3 pg/ml). Arterial blood gas measurements showed a pH of 7.13, arterial partial pressure of carbon dioxide (PaCO₂) of 9.9 mm Hg, and PaO₂ of 156.0 mm Hg, with bicarbonate = 3.3 mmol/L and lactate = 19.6 mmol/L. Blood cultures showed no growth. Urinalysis revealed 1+ protein and no blood leukocytes or bacteria. Chest radiographs and electrocardiogram were unremarkable. A computed tomography (CT) scan of the chest, abdomen, and pelvis revealed only splenomegaly (Figure 2).

Despite aggressive fluid resuscitation, the patient remained persistently hypotensive and was admitted to the intensive care unit. A diagnosis of septic shock was considered, and the patient was started on vasopressors and empirical broad-spectrum antibiotics. The clinical presentation of pancytopenia, splenomegaly, and severe lactic acidosis, without lymphadenopathy, was consistent with hematologic malignancy, especially intravascular lymphoma. In addition to bone marrow biopsy, a random skin biopsy was performed. While awaiting pathological diagnosis, the patient went into shock and experienced multiple-organ dysfunction syndrome involving the circulatory system, liver, and coagulation system (Table 1). He died 5 days after hospitalization. Later, biopsies from the bone marrow and skin revealed intravascular large B-cell lymphoma (Figure 3). A postmortem examination was notable for the demonstration of intravascular large B-cell lymphoma with extensive involvement of the bone marrow, lungs, liver, spleen, kidneys, and adrenals (Figure 4). The rectal carcinoma was confined to invasion of the muscularis propria (Figure 5), and no lymph node or distant metastasis was detected. No infectious focus was found.

### DISCUSSION

The patient was a 64-year-old man with a 2-week history of dyspnea on exertion and weight loss. Key findings included elevated CRP level, refractory shock, pancytopenia, splenomegaly, and lactic acidosis. Despite treatment for presumed septic shock, rapid progression of multiple-organ dysfunction developed, and the patient died 5 days after hospitalization. Postmortem examination revealed evidence of intravascular large B-cell lymphoma, and no infectious focus.

Intravascular lymphoma (IVL) was first described by Pleger and Tapeiner in 1959 as angioendotheliomatosis proliferans systemisata and was initially thought to be
### Table 1  Laboratory data

| Laboratory                      | Admission | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 |
|---------------------------------|-----------|-------|-------|-------|-------|-------|
| WBC count, K/ml                 | 21        | 11.6  | 8.8   | 7.1   | 9.6   | 9.9   |
| Hemoglobin, g/dl                | 9.5       | 8.1   | 8.7   | 7.1   | 9.3   | 9.2   |
| Platelet count, K/ml            | 6.5       | 4.7   | 2.2   | 1.2   | 2.3   | 2.0   |
| Fibrinogen, mg/dl               | 343       | 241   | 212   | 206   | 235   | 233   |
| INR                             | 1.90      | 1.61  | 1.45  | 1.27  | 1.35  | 1.61  |
| D-dimer, μg/ml                  | 7.1       | 7.1   | 9.0   | 8.7   |       |       |
| pH                              | 7.129     | 7.463 | 7.463 | 7.401 | 7.382 | 7.250 |
| Bicarbonate, mmol/L             | 3.3       | 15.0  | 18.6  | 17.9  | 14.4  | 7.6   |
| Lactate, mmol/L                 | 19.6      | 11.7  | 12.1  | 13.4  | 18.3  | 26.5  |
| Total bilirubin, mg/dl          | 3.0       | 3.8   | 6.2   | 12.3  | 19.6  | 24.9  |
| Conjugated bilirubin, mg/dl     | 2.5       | 4.5   | 9.7   |       | 15.8  | 21.8  |
| ALT, U/L                        | 22        | 19    | 19    | 18    | 19    | 20    |
| ALP, U/L                        | 113       | 89    | 102   | 96    | 146   | 208   |
| LDH, U/L                        | 478       | 426   | 465   | 446   | 627   | 845   |
| BUN, mg/dl                      | 101.0     | 97.8  | 76.3  | 65.6  | 67.9  | 75.9  |
| Serum creatinine, mg/dl         | 2.05      | 1.69  | 1.13  | 0.98  | 0.99  | 1.18  |

**Figure 3**  Random skin biopsy. Hematoxylin and eosin stain showing malignant cells within small-vessel lumen (A). CD20 stain (brown) showing malignant cells that are CD20-positive (B)

**Figure 4**  Hematoxylin and eosin staining of postmortem bone marrow (A), lung (B), liver (C), and kidney (D) biopsies revealed atypical lymphoid cells within small-vessel lumen
a neoplasm of endothelial origin, but subsequent immunochemical studies confirmed the lymphoid nature of the neoplasm. Almost all reported cases of IVL have been a neoplasm of B cells. IVL characteristically manifests as fever, pronounced fatigue, decreased appetite, and a decline in functional status. The clinical presentation is diverse and appears to differ by country of origin. In Western countries, patients present most commonly with symptoms related to involvement of the central nervous system (39%) and skin (40%). Bone marrow (32%), liver (26%), and spleen (26%) involvement are less common. Patients from Asian countries preferentially show bone marrow involvement (75%), hepatomegaly (55%), splenomegaly (67%), and hemophagocytic syndrome (61%). Less commonly involved tissues include the nervous system (27%) and skin (15%). Patients often present with the following laboratory abnormalities: anemia (93%), leukopenia (62%), and thrombocytopenia (51%) as well as elevated of serum LDH (97%), CRP (96%), and ferritin (83%). Patients from Western countries and Asian countries differ in the rates of hypoalbuminemia (18% vs. 84%).

The patient's initial presentation was consistent with septic shock, including elevated CRP level, thrombocytopenia, hyperbilirubinemia, renal insufficiency, and refractory shock. Neither microbiology nor autopsy confirmed an infectious source that would account for the clinical picture. Shock is an unusual initial presentation of IVL and has been previously described only in case reports (11–15, Table 2).

Diagnosis of IVL requires a tissue biopsy of an involved organ. Although bone marrow, lymph nodes, peripheral blood, and cerebrospinal fluid are often uninvolved in IVL, the most relevant diagnostic site seems to be the bone marrow in Asian cohorts. Furthermore, random biopsy of apparently normal skin is a valuable, relatively noninvasive, diagnostic tool. The fact that lymphoma cells have been identified from random skin biopsies, not only in European series in which the cutaneous involvement is prevalent, but also in Asian series in which the cutaneous involvement is rare, is remarkable.

This case shows that IVL can be a cause of refractory shock of unknown origin. The patient underwent a prompt evaluation over a period of days to investigate his pancytopenia and splenomegaly. Unfortunately, the ante-mortem diagnosis of IVL could not be established. Prior to diagnostic biopsy, corticosteroid treatment complicates the histological interpretation and may delay definitive diagnosis. However, after the biopsy, corticosteroid
therapy can be tried and may improve critical illness transiently but dramatically, without a diagnostic problem.21

4 | CONCLUSION

In the first 24 h of management of suspected septic shock, the absence of a source of infection is not so uncommon, and the septic focus may be identified later. If no source is found, reassess the differential diagnosis and consider many mimics for sepsis. This case highlights that intravascular lymphoma can be a cause of refractory shock of unknown origin.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS

Hiroki Kato and Shinichi Miyazaki involved in conception and design of study, literature search, and drafting of article. Kodai Yabu, Yumi Sawada, Tadashi Aoyama, and Yoshiharu Nara involved in data acquisition and interpretation. Yuki Kondo and Motoyoshi Yano involved in proofreading the manuscript. All authors read and approved the final manuscript.

ETHICAL APPROVAL

None.

CONSENT

Written informed consent was obtained from the kin to publish this report in accordance with the journal's patient consent policy.

DATA AVAILABILITY STATEMENT

None.

ORCID

Shinichi Miyazaki https://orcid.org/0000-0002-6700-7675

REFERENCES

1. Ponzoni M, Ferreri AJ, Campo E, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007;25:3168-3173.
2. Rajaguru DJ, Bhaskar C, Borgert AJ, et al. Intravascular large B-cell lymphoma in the United States (US): a population-based study using surveillance, epidemiology, and end results program and national cancer database. Leuk Lymphoma. 2017;58:1-9.
3. Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 2009;10:895-902.
4. Pfleger L, Tappeiner J. Zur Kenntnis der systemisierten endotheliomatosen der cutanen blutgefaesse. Hauzart. 1959;10:359-363.
5. Carroll TJ, Schelper RL, Goeken JA, et al. Neoplastic angioendotheliomatosis: Immunopathologic and morphologic evidence for intravascular malignant endotheliomatosis. Am J Clin Pathol. 1986;85:169-175.
6. Song DE, Lee MW, Ryu MH, Kang DW, Kim SJ, Huh J. Intravascular large cell lymphoma of the natural killer cell type. J Clin Oncol. 2007;25:1279-1282.
7. Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br J Haematol. 2004;127:173-183.
8. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular Large B-CELL Lymphoma (IVLBCl): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007;109:478-485.
9. Brunet V, Marouan S, Routy JP, et al. Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: a retrospective study of 29 case reports. Medicine (Baltimore). 2017;96(5):e5985.
10. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-810.
11. Ip M, Chan KW, Chan IK. Systemic inflammatory response syndrome in intravascular lymphomatosis. Intensive Care Med. 1997;23:783-786.
12. Deusch E, Mayr A, Hobisch-Hagen P, et al. Angiotropic large B-cell lymphoma misdiagnosed as urosepsis with multiple organ dysfunction syndrome. Br J Haematol. 1999;43:100-103.
13. Yalamanchili M, Prabhu S, Bradstreet P, Walsh J, Choudhry L. Intravascular lymphomatosis presenting as systemic inflammatory response syndrome. Am J Med Sci. 2002;324:339-341.
14. Fenot M, Lassalle V, Maillard H, Ybarlucea L, Celerier P. Atypical shock and skin lesions revealing lymphoma. Acta Derm Venereol. 2013;93:592-593.
15. Srivalli N, Prasidthratsint K, Ammannagari N, et al. Intravascular large B cell lymphoma presenting as anasarca: an unusual presentation of a rare lymphoma. Ann Hematol. 2013;92:275-276.
16. Gatter KC, Warnke RA. Intravascular large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; 2001:177.
17. Gill S, Melosky B, Haley L, ChanYan C. Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. Am J Med. 2003;114:56-58.
18. Pongpudpunth M, Rattanakaemakorn P, Fleischer AB Jr. Usefulness of random skin biopsy as a diagnostic tool of intravascular lymphoma presenting with fever of unknown origin. Am J Dermatopathol. 2015;37:686-690.
19. Matsue K, Abe Y, Kitadate A, et al. Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. *Blood*. 2019;133:1257-1259.

20. Kan E, Levi I, Benharroch D. Alterations in the primary diagnosis of lymphomas pretreated with corticosteroid agents. *Leuk Lymphoma*. 2011;52:425-428.

21. Beristain X, Azzarelli B. The neurological masquerade of intravascular lymphomatosis. *Arch Neurol*. 2002;59:439-443.

**How to cite this article:** Kato H, Miyazaki S, Yabu K, et al. Intravascular lymphoma masquerading as septic shock. *Clin Case Rep*. 2022;10:e05656. doi:10.1002/ccr3.5656